MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Strona główna・Stock List・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Closed

3.75 -5.06

Buy Sell

Overview

Share price change

24h

Current

Min

3.67

Max

3.95

Key metrics
By Trading Economics
Income	466K -27M
Sales	2M 15M
Profit margin	-178.834
Employees	141
EBITDA	-2M -29M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+292.25% upside

Dividends
By Dow Jones
Next Earnings	4 maj 2026

Market Stats
By TradingEconomics
Market Cap	8.1M 237M
Previous open	8.81
Previous close	3.75

Technical Score

By Trading Central

Confidence

Bearish Evidence

3.17 / 3.4644 Support & Resistance

Voyager Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

10 kwi 2026, 17:04 UTC

Major Market Movers

FDA Rejects Replimune's Melanoma Drug for a Second Time

11 kwi 2026, 00:00 UTC

Earnings

Acquisitions, Mergers, Takeovers

Big Yachts, Big Bucks -- Barrons.com

10 kwi 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

10 kwi 2026, 21:01 UTC

Earnings

Cango Inc.: Files Annual Report on Form 20-F With SEC

10 kwi 2026, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

10 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

10 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

10 kwi 2026, 20:31 UTC

Market Talk

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

10 kwi 2026, 20:10 UTC

Acquisitions, Mergers, Takeovers

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

10 kwi 2026, 19:15 UTC

Market Talk

Global Energy Roundup: Market Talk

10 kwi 2026, 19:15 UTC

Market Talk

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

10 kwi 2026, 19:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

10 kwi 2026, 19:08 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

10 kwi 2026, 18:38 UTC

Market Talk

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

10 kwi 2026, 18:25 UTC

Market Talk

Major News Events

Precious Metals Finish With Weekly Gains -- Market Talk

10 kwi 2026, 18:05 UTC

Market Talk

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

10 kwi 2026, 17:31 UTC

Market Talk

Major News Events

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

10 kwi 2026, 17:26 UTC

Earnings

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

10 kwi 2026, 17:10 UTC

Market Talk

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

10 kwi 2026, 17:00 UTC

Major News Events

Construction Business Taking a Hit From Iran Conflict -- WSJ

10 kwi 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

10 kwi 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

10 kwi 2026, 16:12 UTC

Earnings

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

10 kwi 2026, 16:11 UTC

Earnings

Partners Group: Traditional Programs Contributed $3.3B

10 kwi 2026, 16:10 UTC

Earnings

Partners Group: $5B of New Commitments Came From Bespoke Solutions

10 kwi 2026, 16:10 UTC

Earnings

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

10 kwi 2026, 16:10 UTC

Earnings

Partners Group 1Q New Client Demand $8.3B

10 kwi 2026, 16:09 UTC

Earnings

Partners Group Continued to See Positive Fundraising Momentum in 1Q

10 kwi 2026, 15:54 UTC

Acquisitions, Mergers, Takeovers

Plenitude Completes Acquisition of Acea Energia

10 kwi 2026, 15:38 UTC

Market Talk

Global Energy Roundup: Market Talk

Peer Comparison

Price change

Voyager Therapeutics Inc Forecast

Price Target

By TipRanks

292.25% upside

12 Months Forecast

Average 14.67 USD 292.25%

High 25 USD

Low 8 USD

Based on 8 Wall Street analysts offering 12 month price targets forVoyager Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Voyager Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.17 / 3.4644Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.